Literature DB >> 30478787

Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.

Mohamed Abouegylah1,2, Lior Z Braunstein3, Mohamed A Alm El-Din4, Andrzej Niemierko1, Laura Salama5, Mostafa Elebrashi6, Samantha K Edgington1, Kyla Remillard1, Brian Napolitano1, George E Naoum1, Hoda E Sayegh1, Tessa Gillespie1, Mohamed Farouk2, Abdelsalam A Ismail2, Alphonse G Taghian7.   

Abstract

PURPOSE: Patients with Her2-positive breast cancer treated with trastuzumab have higher rates of cardiotoxicity (CT). Left-breast radiation might increase the risk for CT from cardiac exposure to radiation. The goal of our study is to evaluate the contribution of radiotherapy (RT) in the development of CT in breast cancer patients receiving trastuzumab.
METHODS: Two hundred and two patients were treated with RT and trastuzumab from 2000 to 2014. The RT plans for left-side disease were recalled from archives. The heart, each chamber, and left anterior descending artery (LAD) were independently contoured. New dose-volume histograms (DVH) were generated. Their serial left-ventricular ejection fractions (LVEF) were studied. CT for left and right side were compared using Fisher's exact test. The DVH data were correlated with the predefined cardiac events using actuarial Cox regression analysis.
RESULTS: Compared to the right sided, the left-side cases showed statistically significant development of arrhythmia (14.2%) versus (< 1%) (p < 0.001). Cardiac ischemia was found in 10 patients in left and one patient in right side (p = 0.011). The equivalent uniform dose (EUD) to the left ventricle (LV), right ventricle (RV), and LAD was significantly associated with decrease in LVEF by > 10% (p = 0.037, p = 0.023 and p = 0.049, respectively).
CONCLUSIONS: Among patients treated for left-sided lesions, there were no significant differences in EF decline. However, there was a higher rate of ischemia and arrhythmia compared to those with right-sided disease. The EUD index of LV, RV, and LAD could be considered as a parameter to describe the risk of radiation-induced CT.

Entities:  

Keywords:  Cardiotoxicity; Dose-volume histograms; Radiotherapy; Trastuzumab

Mesh:

Substances:

Year:  2018        PMID: 30478787     DOI: 10.1007/s10549-018-5053-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Dose-volume Histogram Analysis of Knowledge-based Volumetric-modulated Arc Therapy Planning in Postoperative Breast Cancer Irradiation.

Authors:  Eri Inoue; Hiroshi Doi; Hajime Monzen; Mikoto Tamura; Masahiro Inada; Kazuki Ishikawa; Kiyoshi Nakamatsu; Yasumasa Nishimura
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction.

Authors:  Mousumi M Andersen; Diandra Ayala-Peacock; Jessie Bowers; Banks W Kooken; Ralph B D'Agostino; Jennifer H Jordan; Sujethra Vasu; Alexandra Thomas; Heidi D Klepin; Doris R Brown; W Gregory Hundley
Journal:  Am J Cardiol       Date:  2020-04-02       Impact factor: 2.778

3.  Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients.

Authors:  Mutlay Sayan; Zeinab Abou Yehia; Apar Gupta; Deborah Toppmeyer; Nisha Ohri; Bruce G Haffty
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

4.  Implementation of a Knowledge-Based Treatment Planning Model for Cardiac-Sparing Lung Radiation Therapy.

Authors:  Joseph Harms; Jiahan Zhang; Oluwatosin Kayode; Jonathan Wolf; Sibo Tian; Neal McCall; Kristin A Higgins; Richard Castillo; Xiaofeng Yang
Journal:  Adv Radiat Oncol       Date:  2021-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.